Vir’s GSK-Backed Flu Vaccine Candidate Fails Phase II Trial 7/21/2023

Lawmakers Push for Medicare Coverage of Weight-Loss Drugs 7/21/2023

FDA Launches Pilot Program to Develop Better Rare Disease Endpoints 7/21/2023

Biopharma Lawsuit Tracker 2023: Pfizer Settles Trade Secrets Case 7/21/2023

In February 2023, the IciStem consortium, which includes Asier Sáez-Cirión's team at the Institut Pasteur, published details in Nature Medicine of a third case of HIV remission after a bone marrow transplant, involving the Düsseldorf patient. A total of 5 individuals (the Berlin, London, Düsseldorf, New York and City of Hope patients) are now considered as having probably been cured of HIV infection after receiving a bone marrow transplant.

Novartis has acquired DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.

DTx’s lead program, DTx-1252 targets the root cause of CMT1A - the overexpression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally.

Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs by leveraging Flagship's ecosystem of more than 40 human health companies and multiple biotechnology platforms.

Pfizer Inks Potential $7B Deal with Flagship to Deepen Pipeline 7/18/2023

Neumora Races Toward Phase III with New Driver in the Hot Seat 7/18/2023

Novartis Cuts ‘Unique’ Obesity Drug After Poor Phase II Results 7/18/2023

Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen 7/18/2023

Argenx to Sell $750M in Shares Following Promising CIDP Data 7/18/2023

Interview Red Flags: 5 Signs of a Toxic Workplace 7/18/2023

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new or expanded projects in Brazil, India, Vietnam, Ghana and Rwanda that will contribute to the Company's climate action, restore nature, promote biodiversity and build ecological and community resilience, spanning over 100,000 hectares worldwide.

AAIC: Lilly’s Donanemab Data, Analyses Show Additional Benefit for Younger Pa... 7/17/2023

BridgeBio Stages ATTR-CM Comeback with Promising Phase III Data for Acoramidis 7/17/2023

AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress 7/17/2023

Novartis Acquires DTx Pharma in Potential $1B Deal 7/17/2023

FDA Action Alert: Verrica, Citius and Daiichi Sankyo 7/17/2023

FTC Digs Deeper into Pfizer’s $43B Buyout of Seagen 7/17/2023